Amniotic membrane and umbilical cord patch grafts are safe and effective after glaucoma drainage implant surgery, and cosmetic appearance is better than with pericardium grafts, new research shows. Medscape Medical News
Uncategorized
Sutureless valve implantation reduces IOP, use of glaucoma drops
FORT LAUDERDALE, Fla. — Sutureless glaucoma drainage valve implantation significantly reduced IOP and medication use, according to a scientific poster presented here.The poster, presented at the American Glaucoma Society meeting, detailed the safety and efficacy of sutureless valve implantation combined with cataract surgery and cyclophotocoagulation.
Point72 Honored for Health and Wellness Programs by Business Council of Fairfield County
STAMFORD, Conn.–(BUSINESS WIRE)–Point72 Asset Management, L.P. (Point72) has been honored for creating a healthy workplace by the Business Council of Fairfield County. Point72 was recognized for its robust Health and Wellness Program which focuses on…
Inotek Pharmaceuticals Strengthens Patent Estate for Lead Product Candidate Trabodenoson
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek announced that the United States Patent and Trademark Office (“USPTO”) issued a new composition of matter patent for its lead product candidate, trabodenoson.
One-year Outcomes Data from Clinical Trial with ReVision Optics’ Raindrop® Near Vision Inlay for Treating Presbyopia Published in Ophthalmology, the Journal of the American Academy of Ophthalmology
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that results from its ongoing Phase III U.S. FDA clinical study evaluating the Raindrop Near Vision Inlay for the treatment of presbyopia show significantly improved near visual performance and produced a 92% rate of satisfaction among study subjects one year following the procedure. The outcomes data were published in an article entitled “Treatment of P
Uncategorized
SciFluor Life Sciences Awarded Second U.S. Patent for Integrin αvβ3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
CAMBRIDGE, Mass.–(BUSINESS WIRE)–SciFluor Life Sciences announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,266,884 with claims covering the use of the novel compound SF0166.